Post-Transplant Lymphoproliferative Disorder (PTLD) is a rare cancer related to organ and stem cell transplants, as well as Epstein bar disease. There is no nonprofit organization dedicated to this community and the last known gathering involved less than a dozen patients and caregivers, pre-pandemic. When NORD learned of interest… Read More
Join over 1,000 rare disease stakeholders virtually at the World Orphan Drug Congress on Wednesday, April 28, 2021. The conference has over 50 speakers, including NORD’s President and CEO Peter L. Saltonstall, tackling topics on advanced therapies, clinical development, rare disease advocacy, and more.
Register for your free pass today: Read More
Washington, DC, March 25, 2021—The National Organization for Rare Disorders (NORD®) today announced the findings of a new study that details the number of orphan products, generics and biosimilars available to treat rare diseases. NORD commissioned Avalere to conduct the analysis to… Read More
Launched by C-Path and NORD through an FDA grant, the goal of the new platform is to accelerate the development of cures by addressing the need to better characterize rare diseases.
TUCSON, Ariz. and WASHINGTON, September 19, 2019 — The Critical Path Institute… Read More
The collaborative project between the organizations will kick off at a launch meeting in September and will aim to reduce barriers for the development of new treatments and cures for rare diseases.
TUCSON, Ariz. and WASHINGTON,
